万古霉素AUC24计算:贝叶斯法与一阶方程法的比较
该单中心回顾性队列研究纳入978例成人住院患者,比较一阶线性方程与贝叶斯两浓度/单浓度法估算万古霉素AUC24的一致性。线性与贝叶斯两浓度法相关性高(r=0.963,临床一致性87.4%),而线性与贝叶斯单浓度法一致性较低(r=0.823,临床一致性76.8%)。
要点
- 线性法与贝叶斯两浓度法估算万古霉素AUC24高度一致,可考虑互换。
- 线性法与贝叶斯单浓度法一致性欠佳,临床互换需谨慎。
- 高AUC24 extremes时方法间差异可能更明显。
核心结论
- 一阶线性法与贝叶斯两浓度法估算万古霉素AUC24高度一致,变异可接受,可视为可比。
- 线性法与贝叶斯单浓度法变异显著、一致性欠佳,临床互换性存疑。
研究设计与样本
- 单中心回顾性队列研究,纳入2017至2019年978例接受静脉万古霉素的成人住院患者。
- 纳入标准为万古霉素使用至少72小时且获得两次血清药物浓度。
主要发现
- 线性法与贝叶斯两浓度法:r=0.963,临床一致性87.4%,95% LOA -99至76(MD=-11.5 mg*h/L)。
- 贝叶斯两浓度法与单浓度法:r=0.931,临床一致性88.5%,95% LOA -92至113(MD=-10.4 mg*h/L)。
- 线性法与贝叶斯单浓度法:r=0.823,临床一致性76.8%,95% LOA -197至153(MD=-21.9 mg*h/L)。
关键数值与推荐
- 共识指南推荐万古霉素AUC24:MIC靶目标为400-600。
- 指南允许使用贝叶斯软件或一阶方程估算AUC24。
临床怎么用
- 临床可考虑将一阶线性法与贝叶斯两浓度法作为估算万古霉素AUC24的可比方法。
- 应避免将线性法与贝叶斯单浓度法随意互换,尤其在高AUC24值时需谨慎。
局限性
- 单中心回顾性设计可能限制结果外推性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Consensus guidelines recommend targeting a vancomycin area under the curve to minimum inhibitory concentration (AUC24 :MIC) ratio of 400-600 to improve therapeutic success and reduce nephrotoxicity. Although guidelines specify either Bayesian software or first-order equations may be used to estimate AUC24 , there are currently no large studies directly comparing these methods. OBJECTIVE: To compare calculated vancomycin AUC24 using first-order equations with two-drug concentrations at steady state to Bayesian two- and one-concentration estimations. METHODS: This was a single-center, retrospective cohort study of 978 adult hospitalized patients receiving intravenous vancomycin between 2017 and 2019. Patients were included if they received at least 72 h of vancomycin and had two-serum drug concentrations obtained. AUC24 was calculated using first-order analytic (linear), Bayesian two-concentration, and Bayesian one-concentration methods for each patient. The InsightRx™ software platform was used to calculate Bayesian AUC24 . Pearson's correlation and clinical agreement (based on AUC24 classified as subtherapeutic, therapeutic, or supratherapeutic) were used to assess agreement between methods. Bland-Altman plots were used to assess mean difference (MD) and 95% limits of agreement (LOA). RESULTS: Excellent agreement was observed between linear and Bayesian two-concentration methods (r = 0.963, clinical agreement = 87.4%) and Bayesian two-concentration and one-concentration methods (r = 0.931, clinical agreement = 88.5%); however, a degree of variability was noted with 95% LOA -99 to 76 (MD = -11.5 mg*h/L) and -92 to 113 (MD = -10.4 mg*h/L), for the respective comparisons. The agreement between linear and Bayesian one-concentration approaches was less than prior comparisons (r = 0.823, clinical agreement = 76.8%) and demonstrated the greatest amount of variability with 95% LOA -197 to 153 (MD = -21.9 mg*h/L). CONCLUSIONS: Linear and Bayesian two-concentration methods demonstrated high-level agreement with acceptable variability and may be considered comparable to estimate vancomycin AUC24 . As linear and Bayesian one-concentration methods demonstrated significant variability and suboptimal agreement, concerns exist surrounding the interchangeability of these methods in clinical practice, particularly at higher extremes of AUC24 .
引用
- Olney KB, Wallace KL, Mynatt RP, et al. Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy. 2022. PMID: 35134264. doi:10.1002/phar.2670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。